Page 140 - Study Group News Today

Abelacimab, a Dual-Acting Factor XI / XIa Inhibitor, Demonstrated an Unprecedented Reduction in Bleeding in the Largest and Longest Head-toHead Study Comparing a Factor XI Inhibitor to a DOAC 

Anthos Therapeutics halts their phase 2 AZALEA-TIMI 71 trial due to significant reduction in bleeding events with abelacimab, making it a potential breakthrough in anticoagulation therapy for atrial fibrillation.

Email items for the Danville Register & Bees daily Mark your Calendar to news@registerbee.com.

Today 10 a.m. AA - Delta Drop. In, Escanaba. Open meeting; for anyone interested in the recovery process from alcoholism. Handicap accessible. 10 a.m. - Rel

Email items for the Danville Register & Bees daily Mark your Calendar to news@registerbee.com.

Viewership of Korean dramas has grown exponentially during the last decade and so has the number of Korean dramas and films inspired by webtoons.

What Is Glaucoma? Types, Symptoms And Causes

Email items for the Danville Register & Bees daily Mark your Calendar to news@registerbee.com.

Researchers have identified new uses for insulin sensitizers, including in the treatment of polycystic ovary syndrome and infertility.

Email items for the Danville Register & Bees daily Mark your Calendar to news@registerbee.com.